Status:
COMPLETED
A Study of Two Different Formulations of LY3209590 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different for...
Eligibility Criteria
Inclusion
- Are overtly healthy males or non-pregnant females. Additionally, women of childbearing potential must test negative for pregnancy
- Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m²), inclusive at screening
- Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
- Have veins suitable for blood sampling
- Have given written informed consent approved by Lilly and the ethical review board governing the site
Exclusion
- Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Are women who are pregnant or lactating
- Have a history of multiple and/or severe allergic reactions
- Show clinical evidence of HIV, hepatitis C, or hepatitis B, and/or test positive
- Regularly use known drugs of abuse or with positive drug results
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04768842
Start Date
March 3 2021
End Date
September 3 2021
Last Update
September 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research
Leeds, United Kingdom, LS2 9LH